Apogee Therapeutics (APGE) falls after new eczema trial data as investors digest results

Apogee Therapeutics, Inc. (APGE) is down 5.6% today. Here is some analysis on what might have caused this price movement.

Analysis: The company released new 16-week Phase 2 induction dose-optimization data for zumilokibart (APG777) in atopic dermatitis that was broadly positive, but the stock moved lower anyway. This kind of reaction can happen when expectations are already high and investors “sell the news” while scrutinizing dose-response, safety/tolerability, and what the results imply for Phase 3 design and eventual competitiveness.

Details:

The company announced positive 16-week Part B induction dose optimization results from the Phase 2 APEX trial of zumilokibart in moderate-to-severe atopic dermatitis.

The update highlighted efficacy versus placebo (including a reported EASI-75 response rate in the mid-dose cohort) and supports advancing the program toward later-stage development.

Apogee has previously indicated plans to begin Phase 3 studies for zumilokibart in the second half of 2026, contingent on clinical and regulatory outcomes.

This could also reflect short-term positioning/profit-taking after prior strength in the shares going into a key clinical data readout, rather than a fundamental negative change.

Sources:

GlobeNewswire, Apogee Therapeutics Investor Relations, BioPharma Dive

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$APGE Insider Trading Activity

$APGE insiders have traded $APGE stock on the open market 57 times in the past 6 months. Of those trades, 0 have been purchases and 57 have been sales.

Here’s a breakdown of recent trading of $APGE stock by insiders over the last 6 months:

FUNDS MANAGEMENT LLC FAIRMOUNT sold 1,750,000 shares for an estimated $133,525,000
MICHAEL THOMAS HENDERSON (Chief Executive Officer) has made 0 purchases and 21 sales selling 160,000 shares for an estimated $12,186,147.
CARL DAMBKOWSKI (Chief Medical Officer) has made 0 purchases and 16 sales selling 46,100 shares for an estimated $3,492,416.
JANE HENDERSON (Chief Financial Officer) has made 0 purchases and 19 sales selling 23,000 shares for an estimated $1,797,806.

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

EARLY ACCESS

Receive APGE Data Alerts

Real-time alerts on filings, insider trades, and market signals — before everyone else.

Get Alerts →

$APGE Hedge Fund Activity

We have seen 154 institutional investors add shares of $APGE stock to their portfolio, and 87 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

FAIRMOUNT FUNDS MANAGEMENT LLC removed 1,750,000 shares (-85.4%) from their portfolio in Q1 2026, for an estimated $147,297,500
JANUS HENDERSON GROUP PLC added 1,576,626 shares (+324.4%) to their portfolio in Q4 2025, for an estimated $119,003,730
T. ROWE PRICE INVESTMENT MANAGEMENT, INC. added 1,554,546 shares (+107879.7%) to their portfolio in Q4 2025, for an estimated $117,337,132
FMR LLC added 1,037,253 shares (+12.6%) to their portfolio in Q1 2026, for an estimated $87,305,585
BRAIDWELL LP removed 863,678 shares (-60.0%) from their portfolio in Q4 2025, for an estimated $65,190,415
PERCEPTIVE ADVISORS LLC removed 790,267 shares (-33.9%) from their portfolio in Q1 2026, for an estimated $66,516,773
VANGUARD GROUP INC added 612,193 shares (+27.3%) to their portfolio in Q4 2025, for an estimated $46,208,327

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$APGE Analyst Ratings

Wall Street analysts have issued reports on $APGE in the last several months. We have seen 4 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

Rothschild & Co issued a "Buy" rating on 05/01/2026
BTIG issued a "Buy" rating on 01/06/2026
Stephens & Co. issued a "Overweight" rating on 12/17/2025
Deutsche Bank issued a "Buy" rating on 12/10/2025

To track analyst ratings and price targets for $APGE, check out Quiver Quantitative's $APGE forecast page.

$APGE Price Targets

Multiple analysts have issued price targets for $APGE recently. We have seen 11 analysts offer price targets for $APGE in the last 6 months, with a median target of $125.0.

Here are some recent targets:

David Nierengarten from Wedbush set a target price of $135.0 on 05/27/2026
Qize Ding from Rothschild & Co set a target price of $140.0 on 05/01/2026
Joseph Catanzaro from Mizuho set a target price of $110.0 on 03/30/2026
Seamus Fernandez from Guggenheim set a target price of $160.0 on 03/24/2026
Geoff Meacham from Citigroup set a target price of $125.0 on 03/24/2026
Edward Nash from Canaccord Genuity set a target price of $130.0 on 03/24/2026
Julian Harrison from BTIG set a target price of $137.0 on 03/23/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.